Vestal Point and Ryan Wilder hold 6.3% of Taysha Gene Therapies (TSHA)
Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G/A, reporting a beneficial ownership of 6.3% in Taysha Gene Therapies (TSHA). This stake amounts to 18,000,000 shares of common stock, with shared voting and dispositive power. The ownership percentage is based on 287,269,885 shares outstanding as of March 19, 2026.
RTW Investments and R. Wong report 20.7M shares in Taysha (NASDAQ: TSHA)
RTW Investments and Roderick Wong have reported a shared beneficial ownership of 20,689,084 shares in Taysha Gene Therapies (NASDAQ: TSHA), representing a 7.0% stake. This figure includes the assumed exercise of 7,008,836 warrants held by the reporting persons. The disclosure is publicly available through a SCHEDULE 13G/A filing with the SEC.
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026
Taysha Gene Therapies (NASDAQ: TSHA) announced its Q1 2026 financial results, highlighting FDA alignment for a Biologics License Application (BLA) submission pathway for TSHA-102. The company also reported progress in patient dosing for the REVEAL pivotal trial and ongoing enrollment in the ASPIRE trial, with TSHA-102 showing generally good tolerability. Additionally, Taysha initiated a BLA-enabling PPQ campaign for TSHA-102 using a commercial manufacturing process.
Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights
Canaccord reiterated its Buy rating on Taysha Gene Therapies, Inc. (TSHA) with a $17 price target after the company reported Q1 2026 results. Taysha confirmed progress with the FDA on its Biologics License Application (BLA) for TSHA-102 and continues enrollment in the ASPIRE trial, expecting dosing completion for both trials in Q2 2026. The company focuses on developing AAV-based gene therapies for central nervous system monogenic diseases.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2026 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) discussed its Q1 2026 financial results, reporting a net loss of $42.4 million or $0.12 per share. The company underscored progress in its TSHA-102 gene therapy program for Rett syndrome, including regulatory alignment with the FDA for a potential expedited BLA submission based on 6-month interim data. Taysha also highlighted ongoing clinical trial advancements and promising preclinical data validating its minimally invasive intrathecal delivery approach.
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17
CCORF has reiterated its Buy rating for Taysha Gene Therapies (TSHA.US) and maintained its target price at $17. This indicates a continued positive outlook from the analyst firm for the gene therapy company.
Taysha Gene Therapies Q1 net loss widens on higher R&D costs
Taysha Gene Therapies reported a widening net loss in the first quarter, primarily driven by increased research and development costs. The biotechnology company's financial results reflect higher expenditures in its drug development pipeline.
Taysha Gene Therapies Q1 2026 Earnings Call Transcript
Taysha Gene Therapies (TSHA) reported its Q1 2026 financial results, highlighting significant progress in its TSHA-102 gene therapy program for Rett syndrome. The company reaffirmed FDA alignment on a BLA submission pathway, including the potential for approval based on a six-month interim analysis, and initiated a BLA-enabling manufacturing campaign. Dosing in pivotal trials is on track for completion in Q2 2026, with an emphasis on rigorous data collection and the consistent, deepening effects of the treatment across various age groups.
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
Needham has reiterated its Buy rating for Taysha Gene Therapies (TSHA.US) and maintained its target price at $12. This indicates a continued positive outlook on the company's stock performance from the analyst firm.
Taysha Gene Therapies: Runway to Fund Planned Operating Expenses Into 2028 >TSHA
Taysha Gene Therapies announced that its current cash, cash equivalents, and marketable securities, combined with projected revenue from its recent licensing agreement with Astellas Pharma, are expected to fund planned operating expenses into 2028. This financial runway projection includes the repayment of a $20 million venture debt facility and is based on a refined operating plan. The company aims to advance its gene therapy pipeline for neurological diseases, particularly focusing on TSHA-102 for Rett syndrome.
A 6-month trial readout could shape Taysha's gene therapy filing
Taysha Gene Therapies reported its Q1 2026 financial results, which included a net loss of $42.4 million, and provided a corporate update emphasizing FDA alignment for a Biologics License Application (BLA) pathway for TSHA-102. The company plans to submit based on a six-month interim analysis from the REVEAL pivotal trial and expects to complete dosing in its REVEAL and ASPIRE trials in Q2 2026. Taysha also reaffirmed that TSHA-102 has been well tolerated with no serious adverse events and has sufficient cash to fund operations into 2028.
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies (Nasdaq: TSHA) reported its first-quarter 2026 financial results, highlighting reaffirmation of FDA alignment for the TSHA-102 BLA pathway, including potential approval based on a 6-month interim analysis of the REVEAL pivotal trial. The company advanced dosing in the REVEAL trial and enrollment in the ASPIRE trial, expecting completion in Q2 2026, while maintaining a favorable safety profile for TSHA-102 with no treatment-related serious adverse events. Taysha also initiated a BLA-enabling PPQ campaign for TSHA-102 and expects its current cash resources to fund operations into 2028.
Taysha Gene Therapies (NASDAQ: TSHA) widens Q1 loss but affirms TSHA-102 BLA pathway
Taysha Gene Therapies (NASDAQ: TSHA) reported a wider net loss of $42.4 million in Q1 2026, compared to $21.5 million in the prior year, primarily due to increased R&D and G&A expenses for its Rett syndrome gene therapy TSHA-102. Despite the increased loss, the company reaffirmed FDA alignment on the Biologics License Application (BLA) pathway for TSHA-102, including pivotal trial design and the potential for submission based on interim analysis. Taysha ended the quarter with $276.6 million in cash, which is expected to fund operations into 2028, and is on track to complete dosing for its REVEAL and ASPIRE trials in Q2 2026.
Taysha Gene earnings loom with pivotal trial data on horizon By Investing.com
Taysha Gene Therapies Inc. is set to report its first-quarter results, with investor attention primarily on the progression of its lead gene therapy candidate, TSHA-102, for Rett syndrome, rather than near-term revenue. Analysts have a "strong buy" rating on the stock, anticipating significant upside based on upcoming clinical trial data. The company expects to complete patient dosing for its pivotal REVEAL trial and younger-population ASPIRE trial, with updated Part A data from REVEAL also expected in the second quarter.
Taysha Gene Therapies stock hits 52-week high at 6.77 USD
Taysha Gene Therapies Inc. (TSHA) stock reached a new 52-week high of $6.77, marking a 170% return over the past year and achieving a market capitalization of $1.9 billion. Despite this surge, InvestingPro data indicates the stock is currently trading above its Fair Value and analysts do not anticipate profitability this year, though the company has strong liquidity. Recent developments include positive preclinical data for its Rett syndrome gene therapy (TSHA-102) and increased price targets from several analysts based on trial progress.
Taysha Gene Therapies (Nasdaq:TSHA) - Stock Analysis
Taysha Gene Therapies (TSHA) is a clinical-stage biotechnology company focused on gene therapies for severe central nervous system diseases, particularly Rett syndrome with its lead asset TSHA-102. The company recently reaffirmed FDA alignment for TSHA-102's Biologics License Application (BLA) pathway and reported a Q1 2026 net loss of US$42.4 million, with US$276.6 million cash on hand expected to fund operations for at least 12 months. Despite ongoing losses and share price volatility, analysts have raised price targets, citing progress in clinical trials and FDA designations, though insider selling and past share dilution are noted risks.
Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday
Taysha Gene Therapies (TSHA) is scheduled to release its Q1 2026 earnings before market open on Wednesday, May 6th. Analysts are forecasting an earnings per share of ($0.10) and revenue of $0.756 million for the quarter. The company previously exceeded estimates in the last quarter, reporting ($0.08) EPS against a consensus of ($0.11) and revenue of $5.49 million against an expected $1.89 million.
Five new Taysha hires get 188,000 stock units under Nasdaq rule
Taysha Gene Therapies announced that its Compensation Committee granted 188,000 restricted stock units (RSUs) to five new employees on May 1, 2026, under its 2023 Inducement Plan. These RSUs, acting as an inducement for employment, will vest in four equal annual installments starting on the first anniversary of the vesting commencement date, contingent on continued service. This move is consistent with Nasdaq Listing Rule 5635(c)(4) and is considered a routine equity inducement by analysts.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. announced that its Compensation Committee granted restricted stock units (RSUs) representing 188,000 shares of common stock to five new employees. These grants were made on May 1, 2026, under the company's 2023 Inducement Plan, as an inducement for their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments, contingent upon continued service.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. recently announced an inducement grant of restricted stock units (RSUs) to five new employees, totaling 188,000 shares of common stock. This grant was made under the company's 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to attract new talent. The RSUs will vest in equal annual installments over four years, contingent on the employees' continued service.
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
Taysha Gene Therapies announced it will release its first-quarter 2026 financial results and host a conference call and webcast on May 6, 2026, at 8:30 AM Eastern Time. The company, a clinical-stage biotechnology firm, focuses on AAV-based gene therapies for severe monogenic central nervous system diseases, with its lead program TSHA-102 targeting Rett syndrome.
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
Taysha Gene Therapies (Nasdaq: TSHA) will report its first-quarter 2026 financial results and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time. The company, a clinical-stage biotechnology firm, focuses on AAV-based gene therapies for severe monogenic CNS diseases, with its lead program TSHA-102 targeting Rett syndrome.
Biotech Taysha pairs its Q1 results with a corporate update on May 6
Taysha Gene Therapies announced it will release its first quarter 2026 financial results and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM ET. Investors can access the live webcast via the company’s website, with an archived replay available afterward. The announcement also provides key financial figures and outlines the company's historical trends and market context ahead of the earnings call.
Earnings update from Taysha Gene Therapies expected next week
Taysha Gene Therapies, Inc. is scheduled to release its first-quarter 2026 earnings and provide a corporate update next week. The company has directed stakeholders to its website for additional details as the earnings release date approaches.
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
Taysha Gene Therapies, Inc. announced it will release its financial results for the first quarter ended March 31, 2026, and host a conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time. The clinical-stage biotechnology company focuses on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system, with its lead program TSHA-102 targeting Rett syndrome. An archived replay of the webcast will be available on the company's website.
Taysha Gene Therapies to Present New Preclinical Data
Taysha Gene Therapies announced it will present new preclinical data on TSHA-102 for Rett syndrome at the ASGCT 2026 Annual Meeting. The data show that the self-complementary AAV9 (scAAV9) construct in TSHA-102 enables significantly higher MECP2 protein expression and that the miniaturized MECP2 protein is functionally comparable to full-length MECP2. These findings validate TSHA-102's construct design and support clinical data showing functional gains in patients.
Taysha says Rett gene therapy design drove 30-fold higher MeCP2
Taysha Gene Therapies announced new preclinical in vitro data for its gene therapy TSHA-102 for Rett syndrome, demonstrating that its scAAV9 construct delivers approximately 30-fold higher MeCP2 protein expression compared to single-stranded AAV9. The data also confirmed that the miniaturized MeCP2 protein used in TSHA-102 is functionally comparable to the full-length protein. These findings support the design of TSHA-102 and its lumbar intrathecal delivery, providing translational backing for the early clinical observations from the REVEAL Phase 1/2 trials.
Taysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual Meeting
Taysha Gene Therapies announced new preclinical data for its gene therapy candidate TSHA-102 for Rett syndrome, highlighting that its self-complementary AAV9 (scAAV9) vector achieves 30-fold higher MeCP2 protein expression compared to the single-stranded AAV9 (ssAAV9) vector. The data also confirm the functional similarity of the miniaturized MeCP2 (miniMeCP2) protein to the full-length version. These findings, which validate TSHA-102's design and support ongoing Phase 1/2 clinical trials, will be presented at the ASGCT Annual Meeting in May 2026.
Taysha Gene Therapies, Inc. ($TSHA) CEO and Director 2025 Pay Revealed
Taysha Gene Therapies, Inc.'s CEO, Sean Nolan, received an estimated compensation of $4,099,065 in 2025, marking a 15.34% decrease from the previous year. This information comes from a recent SEC filing. The article also details insider trading activities, hedge fund movements, and recent analyst ratings and price targets for TSHA stock.
Taysha Gene Therapies stock hits 52-week high at 6.7 USD
Taysha Gene Therapies (TSHA) stock has reached a new 52-week high of $6.70, reflecting a 249% surge over the past year due to its promising gene therapy pipeline for neurological diseases. Despite a widened net loss for the full year 2025, investor optimism is fueled by ongoing gene therapy trials, leading several analysts to raise their price targets and reiterate Buy or Strong Buy ratings. InvestingPro analysis suggests the stock is currently overvalued and in overbought territory.
Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels
Taysha Gene Therapies (TSHA) has seen its stock price surge by 343.45% over the past year and 22.48% year-to-date, making it one of the top small-cap biotech stocks among hedge funds. Analysts at Needham and Canaccord Genuity have reiterated "buy" ratings with raised price targets. The company recently granted restricted stock units and stock options to new employees as an inducement for employment.
Executive pay, board seats and auditor up for TSHA (NASDAQ: TSHA) vote
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) has announced the agenda for its annual stockholder meeting on June 1, 2026, which includes voting on the election of two Class III directors, the ratification of Deloitte & Touche LLP as the independent auditor, and a non-binding advisory vote on executive compensation. Stockholders will also decide the preferred frequency for future "say-on-pay" votes. The proxy statement details executive compensation for 2025, with CEO Sean Nolan receiving over $4 million, and lists major beneficial owners.
TSHA Jumps As Taysha Gene Therapies Wins Target Hike
Taysha Gene Therapies Inc. (TSHA) saw its stock jump 7.56% after Canaccord raised its price target to $17 and reiterated a Buy rating, citing strong Q4 2025 revenue ($9.8M vs. $5.9M consensus) and a narrowed net loss. The company's lead asset, TSHA-102, is progressing through pivotal trials with a cash runway extending into 2028, reducing near-term financing risks and shifting focus to clinical execution. Despite a recent insider sale, analyst sentiment remains positive, emphasizing the high-risk, high-upside potential in AAV CNS gene therapy.
Taysha Gene Therapies Sees Unusually High Options Volume (NASDAQ:TSHA)
Taysha Gene Therapies (NASDAQ:TSHA) experienced an unusual surge in options trading, with call option volume increasing by 2,571% on Thursday, indicating strong bullish sentiment. This comes despite recent insider selling, including significant share sales by the CEO and another insider. Wall Street analysts maintain a "Buy" consensus rating on the stock with an average price target of $11.64.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Brokerages
Taysha Gene Therapies (NASDAQ:TSHA) has received an average "Buy" rating from thirteen brokerages, with an average 1-year price target of $11.64, significantly higher than its current share price. Despite notable insider selling totaling $2.77 million in the last three months, institutional investors hold a substantial 77.7% ownership. The company, a clinical-stage gene therapy developer, recently surpassed quarterly earnings estimates with an EPS of ($0.08) and revenue of $5.49 million.
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
Needham has reiterated its Buy rating on Taysha Gene Therapies (TSHA.US) and maintained its target price at $12. This indicates a continued positive outlook from the firm regarding Taysha's stock performance and potential.
Taysha Gene Therapies stock hits 52-week high at 6.02 USD By Investing.com
Taysha Gene Therapies (TSHA) stock recently hit a new 52-week high of $6.02, reflecting a 398.73% surge over the past year, though InvestingPro's Fair Value analysis suggests it may be overvalued. Despite reporting a net loss of $109.0 million in 2025, investor sentiment remains positive due to promising gene therapy trials and analyst confidence, with several firms raising price targets and maintaining "Buy" or "Overweight" ratings. The company, focused on gene therapies for central nervous system diseases, maintains a strong balance sheet with substantial cash reserves.
This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to Buy
Taysha Gene Therapies Inc. (TSHA) is highlighted as a top healthcare penny stock, favored by hedge funds, following a reiterated Buy rating and raised price target of $17 from Canaccord. The company's TSHA-102 gene therapy for Rett syndrome is progressing through clinical trials, with dosing completion confirmed for its REVEAL and ASPIRE trials. Canaccord's confidence stems from TSHA's impressive 258% return over the past year, significant milestone gains, and a clean safety profile in pivotal trials.
5 Best Healthcare Penny Stocks to Buy According to Hedge Funds
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is highlighted as a top healthcare penny stock, favored by hedge funds, with a significant upside potential of 173.42% and 32 hedge funds holding stakes. Canaccord reiterated its Buy rating and raised the price target to $17 due to the stock's impressive 258% return over the past year and progress in its REVEAL and ASPIRE trials for Rett syndrome. The company, a clinical-stage biotechnology firm, is developing TSHA-102, an AAV9-based gene therapy for severe genetic disorders of the central nervous system.
TSHA (NASDAQ: TSHA) president sells 200K shares under 10b5-1 plan
Taysha Gene Therapies, Inc. President and Head of R&D Nagendran Sukumar exercised stock options for 19,021 shares and subsequently sold 200,000 common shares at a weighted average price of $4.46 per share. This sale was conducted under a Rule 10b5-1 trading plan adopted in June 2025. Following these transactions, Sukumar still directly holds 1,136,410 common shares and 455,920 stock options.
Taysha Gene Therapies (NASDAQ: TSHA) insider selling 200,000 shares
A Form 144 filing indicates that Sukumar Nagendran, an insider at Taysha Gene Therapies (NASDAQ: TSHA), proposes to sell 200,000 shares of the company's stock. The proposed sale, dated January 12, 2026, is valued at $942,740 and includes previously granted RSUs and stock options. This is a routine disclosure required for insider sales, providing transparency about the planned transaction.
Taysha Gene Therapies (TSHA) Is Up 5.6% After FDA Clears Rett Trial And Grants New Equity Awards - Has The Bull Case Changed?
Taysha Gene Therapies (TSHA) saw a 5.6% stock increase after the FDA cleared its ASPIRE clinical trial for TSHA-102, an investigational gene therapy for Rett syndrome, and the company granted new equity awards. This development reinforces TSHA-102 as a core near-term catalyst and solidifies the regulatory path, although trial performance and cash burn remain key risks. Analysts anticipate substantial revenue and earnings growth by 2029, suggesting a significant upside potential for the stock.
Taysha Gene Therapies (TSHA) Price Target Increased by 12.72% to 9.96
Taysha Gene Therapies (TSHA) has seen its price target increased by 12.72% to $9.96. This adjustment suggests a positive outlook from analysts regarding the company's future stock performance.
Taysha Gene Therapies (TSHA) Price Target Increased by 12.72% to 9.96
This article reports a 12.72% increase in the price target for Taysha Gene Therapies (TSHA), raising it to $9.96. The adjustment reflects updated analyst expectations for the company's stock performance.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 earnings call transcript
NULL
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.9% on Analyst Upgrade
Taysha Gene Therapies (NASDAQ:TSHA) saw its shares rise by 6.9% after Canaccord Genuity upgraded its price target from $14.00 to $17.00. The company also reported stronger-than-expected quarterly earnings and revenue, though insider selling occurred recently. Institutional investors hold a significant portion of its stock.
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $17.00
Canaccord Genuity Group raised its price target for Taysha Gene Therapies (NASDAQ:TSHA) to $17.00 from $14.00, maintaining a "buy" rating with a potential upside of 262.09% from its current price of $4.70. The company recently exceeded quarterly EPS and revenue estimates, though insiders have sold a significant number of shares. Analysts currently have an average "Buy" rating and a target price of $11.64 for Taysha Gene Therapies.
Canaccord raises Taysha Gene Therapies price target on trial progress
Canaccord raised its price target on Taysha Gene Therapies (NASDAQ:TSHA) shares to $17 from $14, maintaining a Buy rating, citing trial progress. The company expects to complete dosing in its REVEAL and ASPIRE trials in Q2 2026 and anticipates updated Part A data for REVEAL, showing 100% milestone gain in patients. Despite a widened net loss in 2025, other firms like Jefferies, Raymond James, and Cantor Fitzgerald have also raised price targets or reiterated positive ratings based on the advancements in Taysha's gene therapy trials.
Capricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA
Capricorn Fund Managers Ltd has acquired a new stake of 300,000 shares in Taysha Gene Therapies (NASDAQ: TSHA) during the fourth quarter, valued at approximately $1.65 million. This investment comes amidst mixed insider activity, with CFO Kamran Alam and CEO Sean P. Nolan selling a combined 215,757 shares in January. Despite insider sales, analysts maintain a "Buy" rating for Taysha Gene Therapies with a consensus price target of $11.09, following recent positive earnings results.
Citizens Maintains Taysha Gene Therapies (TSHA) Market Outperform Recommendation
This article reports that Citizens has reiterated its Market Outperform rating for Taysha Gene Therapies (TSHA). No further details about the reasons for this rating or any financial analysis are provided in the current content.
